دورية أكاديمية
أعرض في EDS

Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.

التفاصيل البيبلوغرافية
العنوان: Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists.
المؤلفون: Lindsay CR; Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK. colin.lindsay@manchester.ac.uk.; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK. colin.lindsay@manchester.ac.uk.; Cancer Research UK Lung Cancer Centre of Excellence, London and Manchester, Manchester, UK. colin.lindsay@manchester.ac.uk., Shaw EC; Department of Histopathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Moore DA; Cancer Research UK Lung Cancer Centre of Excellence, London and Manchester, Manchester, UK.; Department of Cellular Pathology, University College London Hospital NHS Foundation Trust, London, UK., Rassl D; Department of Histopathology, Papworth Hospital, Cambridge, UK., Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, London and Manchester, Manchester, UK.; Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK., Steele N; Department of Medical Oncology, the Beatson West of Scotland Cancer Centre, Glasgow, UK., Naheed S; Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Dick C; Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK., Taylor F; Department of Medical Oncology, Weston Park Cancer Centre, Sheffield, UK., Adderley H; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Black F; Department of Histopathology, the Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK., Summers Y; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Evans M; Department of Histopathology, Black Country Pathology Services, Royal Wolverhampton NHS Trust, Wolverhampton, UK., Rice A; Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust, London, UK., Fabre A; Department of Histopathology, St Vincent's Healthcare Group, Dublin, Ireland., Wallace WA; Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK.; Division of Pathology, the University of Edinburgh, Edinburgh, UK., Nicholson S; Department of Histopathology, St James's Hospital, Dublin, Ireland., Haragan A; Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, UK., Taniere P; Department of Histopathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Nicholson AG; Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust, London, UK.; National Heart and Lung Institute, Imperial College, London, UK., Laing G; Department of Pathology, Aberdeen University School of Medicine and Aberdeen Royal Infirmary, Aberdeen, UK., Cave J; Department of Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Forster MD; Cancer Research UK Lung Cancer Centre of Excellence, London and Manchester, Manchester, UK.; Department of Oncology, University College of London Hospital and UCL Cancer Institute, London, UK., Blackhall F; Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK.; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.; Cancer Research UK Lung Cancer Centre of Excellence, London and Manchester, Manchester, UK., Gosney J; Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, UK., Popat S; Lung Unit, The Royal Marsden Hospital, London, UK.; Section of Clinical Studies, The Institute of Cancer Research, London, UK., Kerr KM; Department of Pathology, Aberdeen University School of Medicine and Aberdeen Royal Infirmary, Aberdeen, UK.
المصدر: British journal of cancer [Br J Cancer] 2021 Oct; Vol. 125 (9), pp. 1210-1216. Date of Electronic Publication: 2021 Sep 06.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
مواضيع طبية MeSH: Carcinoma, Large Cell/*pathology , Carcinoma, Neuroendocrine/*pathology , Lung Neoplasms/*pathology, Biomarkers, Tumor/metabolism ; Carcinoma, Large Cell/metabolism ; Carcinoma, Large Cell/therapy ; Carcinoma, Neuroendocrine/metabolism ; Carcinoma, Neuroendocrine/therapy ; Clinical Trials as Topic ; Consensus ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/therapy ; Precision Medicine ; Treatment Outcome
مستخلص: Over the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.
(© 2021. The Author(s).)
References: Carlisle, J. W. & Ramalingam, S. S. A banner year for immunotherapy and targeted therapy. Nat. Rev. Clin. Oncol. 16, 79–80 (2019). (PMID: 3053830510.1038/s41571-018-0138-4)
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B. et al. The 2015 World Health Organization classification of lung tumors. Impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol. 10, 1243–1260 (2015). (PMID: 2629100810.1097/JTO.0000000000000630)
Lo Russo, G., Pusceddu, S., Proto, C., Macerelli, M., Signorelli, D., Vitali, M. et al. Treatment of lung large cell neuroendocrine carcinoma. Tumour Biol. 37, 7047–7057 (2016). (PMID: 2694380010.1007/s13277-016-5003-4)
Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167–2177 (2014). (PMID: 2547069410.1056/NEJMoa1408440)
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D. W. et al. Alectinib versus crizotinib in untreated ALK-positive non-small cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017). (PMID: 2858627910.1056/NEJMoa1704795)
Camidge, D. R., Kim, H. R., Ahn, M. J., Yang, J. C., Han, J. Y., Lee, J. S. et al. Brigatinib versus crizotinib in ALK-positive non-small cell lung cancer. N. Engl. J. Med. 379, 2027–2039 (2018). (PMID: 3028065710.1056/NEJMoa1810171)
Travis, W. D., Linnoila, R. I., Tsokos, M. G., Hitchcock, C. L., Cutler, G. B. Jr, Nieman et al. Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am. J. Surg. Pathol. 15, 529–553 (1991). (PMID: 170955810.1097/00000478-199106000-00003)
Rekhtman, N. & Travis, W. D. Large no more: the journey of pulmonary large cell carcinoma from common to rare entity. J. Thorac. Oncol. 14, 1125–1127 (2019). (PMID: 3123503310.1016/j.jtho.2019.04.014)
Camidge, D. R., Doebele, R. C. & Kerr, K. M. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat. Rev. Clin. Oncol. 16, 341–355 (2019). (PMID: 3071884310.1038/s41571-019-0173-9)
Le Treut, J., Sault, M. C., Lena, H., Souquet, P. J., Vergnenegre, A., Le Caer, H. et al. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann. Oncol. 24, 1548–1552 (2013). (PMID: 2340672910.1093/annonc/mdt009)
Niho, S., Kenmotsu, H., Sekine, I., Ishii, G., Ishikawa, Y., Noguchi, M. et al. Combination chemotherapy with irinotecan and cisplatin for large cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J. Thorac. Oncol. 8, 980–984 (2013). (PMID: 2377438510.1097/JTO.0b013e31828f6989)
Derks, J. L., Dingemans, A. C., van Suylen, R. J., den Bakker, M. A., Damhuis, R. A. M., van den Broek, E. C. et al. Is the sum of positive neuroendocrine immunohistochemical stains useful for diagnosis of large cell neuroendocrine carcinoma (LCNEC) on biopsy specimens? Histopathology 74, 555–566 (2019). (PMID: 30485478685018410.1111/his.13800)
Inage, T., Nakajima, T., Fujiwara, T., Sakairi, Y., Wada, H., Suzuki, H. et al. Pathological diagnosis of pulmonary large cell neuroendocrine carcinoma by endobronchial ultrasound-guided transbronchial needle aspiration. Thorac. Cancer 9, 273–277 (2018). (PMID: 2927158810.1111/1759-7714.12576)
Przygodzki, R. M., Finkelstein, S. D., Langer, J. C., Swalsky, P. A., Fishback, N., Bakker, A. et al. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am. J. Pathol. 148, 1531–1541 (1996). (PMID: 86239221861560)
Rusch, V. W., Klimstra, D. S. & Venkatraman, E. S. Molecular markers help characterize neuroendocrine lung tumors. Ann. Thorac. Surg. 62, 798–809 (1996). (PMID: 878401110.1016/S0003-4975(96)00435-3)
Jones, M. H., Virtanen, C., Honjoh, D., Miyoshi, T., Satoh, Y., Okumura, S. et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small cell and large cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 363, 775–781 (2004). (PMID: 1501648810.1016/S0140-6736(04)15693-6)
Clinical Lung Cancer Genome Project (CLCGP). Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci. Transl. Med. 5, 209ra153 (2013).
Bari, M. F., Brown, H., Nicholson, A. G., Kerr, K. M., Gosney, J. R., Wallace, W. A. et al. BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas. Histopathology 64, 547–556 (2014). (PMID: 2426689710.1111/his.12278)
Rekhtman, N., Pietanza, M. C., Hellmann, M. D., Naidoo, J., Arora, A., Won, H. et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin. Cancer Res. 22, 3618–3629 (2016). (PMID: 26960398499577610.1158/1078-0432.CCR-15-2946)
George, J., Walter, V., Peifer, M., Alexandrov, L. B., Seidel, D., Leenders, F. et al. Integrative genomic profiling of large cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat. Commun. 9, 1048 (2018). (PMID: 29535388584959910.1038/s41467-018-03099-x)
Miyoshi, T., Umemura, S., Matsumura, Y., Mimaki, S., Tada, S., Makinoshima, H. et al. Genomic profiling of large cell neuroendocrine carcinoma of the lung. Clin. Cancer Res. 23, 757–765 (2017). (PMID: 2750761810.1158/1078-0432.CCR-16-0355)
Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014). (PMID: 10.1038/nature13385)
Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H. et al. EGFR-mutant adenocarcinomas that transform to small cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J. Clin. Oncol. 37, 278–285 (2019). (PMID: 3055036310.1200/JCO.18.01585)
Calles, A., Sholl, L. M., Rodig, S. J., Pelton, A. K., Hornick, J. L., Butaney, M. et al. Immunohistochemical loss of LKB1 is a biomarker for more aggressive biology in KRAS-mutant lung adenocarcinoma. Clin. Cancer Res. 21, 2851–2860 (2015). (PMID: 2573750710.1158/1078-0432.CCR-14-3112)
Derks, J. L., Leblay, N., Thunnissen, E., van Suylen, R. J., den Bakker, M., Groen, H. J. M. et al. Molecular subtypes of pulmonary large cell neuroendocrine carcinoma predict chemotherapy treatment outcome. Clin. Cancer Res. 24, 33–42 (2018). (PMID: 2906650810.1158/1078-0432.CCR-17-1921)
De Pas, T. M., Giovannini, M., Manzotti, M., Trifirò, G., Toffalorio, F., Catania, C. et al. Large cell neuroendocrine carcinoma of the lung harbouring EGFR mutation and responding to gefitinib. J. Clin. Oncol. 29, e819–e822 (2011). (PMID: 2204296310.1200/JCO.2011.36.2251)
Aroldi, F., Bertocchi, P., Meriggi, F., Abeni, C., Ogliosi, C., Rota, L. et al. Tyrosine kinase inhibitors in EGFR-mutated large-cell neuroendocrine carcinoma of the lung? A case report. Case Rep. Oncol. 7, 478–483 (2014). (PMID: 25202262415419510.1159/000365413)
Omachi, N., Shimizu, S., Kawaguchi, T., Tezuka, K., Kanazu, M., Tamiya, A. et al. A case of large cell neuroendocrine carcinoma harbouring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib. J. Thorac. Oncol. 9, e40–e42 (2014). (PMID: 2482867010.1097/JTO.0000000000000103)
Quinn, A. M., Chaturvedi, A. & Nonaka, D. High-grade neuroendocrine carcinoma of the lung with carcinoid morphology: a study of 12 cases. Am. J. Surg. Pathol. 41, 263–270 (2017). (PMID: 2787951310.1097/PAS.0000000000000767)
Alcala, N., Leblay, N., Gabriel, A. A. G., Mangiante, L., Hervas, D., Giffon, T. et al. Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat. Commun. 10, 3407 (2019). (PMID: 31431620670222910.1038/s41467-019-11276-9)
Simbolo, M., Barbi, S., Fassan, M., Mafficini, A., Ali, G., Vicentini, C. et al. Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations. J. Thorac. Oncol. 14, 1651–1661 (2019). (PMID: 3108534110.1016/j.jtho.2019.05.003)
Travis, W. D. Advances in neuroendocrine lung tumors. Ann. Oncol. 21, vii65–vii71 (2010). (PMID: 2094364510.1093/annonc/mdq380)
Rami-Porta, R., Wittekind, C. & Goldstraw, P. Complete resection in lung cancer: proposed definition. Lung Cancer 49, 25–33 (2005). (PMID: 1594958710.1016/j.lungcan.2005.01.001)
Raman, V., Jawitz, O. K., Yang, C.-F. J., Voigt, S. L., Tong, B. C., D’Amico, T. A. et al. Outcomes for surgery in large cell lung neuroendocrine cancer. J. Thorac. Oncol. 14, 2143–2151 (2019). (PMID: 31557535729386410.1016/j.jtho.2019.09.005)
Kujtan, L. A., Muthukumar, V., Toor, M., Kennedy, K. F., Masood, A., Davis, J. R. et al. The role of adjuvant therapy in the management of resected large cell neuroendocrine carcinoma (LCNEC) of the lung: a national cancer database (NCDB) analysis. J. Clin. Oncol. 35, 8529 (2017). (PMID: 10.1200/JCO.2017.35.15_suppl.8529)
Derks, J., van Suylen, R. J., Thunnissen, E., den Bakker, M., Groen, H., Smit, E. et al. Why we should improve current practice of diagnosing and treating pulmonary large cell neuroendocrine carcinomas in patients with advanced disease. Eur. Respir. J. 50, 1701658 (2017). (PMID: 2907454810.1183/13993003.01658-2017)
Christopoulos, P., Engel-Riedel, W., Grohé, C., Kropf-Sanchen, C., von Pawel, J., Gütz, S. et al. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large cell neuroendocrine lung carcinoma: a multicenter phase II trial. Ann. Oncol. 28, 1898–1902 (2017). (PMID: 2853518110.1093/annonc/mdx268)
Sabari, J. K., Julian, R. A., Ni, A., Halpenny, D., Hellmann, M. D., Drilon, A. E. et al. Outcomes of advanced pulmonary large cell neuroendocrine carcinoma stratified by RB1 loss, SLFN11 expression, and tumor mutational burden. J. Clin. Oncol. 36, e20568 (2018). (PMID: 10.1200/JCO.2018.36.15_suppl.e20568)
Hellman, M. D., Paz-Ares, L., Caro, R. B., Zurawski, B., Kim, S.-W., Costa, E. C. et al. Nivolumab plus ipilimumab in advanced non–small cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019). (PMID: 10.1056/NEJMoa1910231)
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F. et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822–835 (2018). (PMID: 29773717603043310.1158/2159-8290.CD-18-0099)
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S. et al. Tracking the evolution of non-small cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017). (PMID: 2844511210.1056/NEJMoa1616288)
Nartey, Y., Stewart, I., Khakwani, A., Beattie, V., Wilcock, A., Woolhouse, I. et al. Is the english cancer patient experience survey representative? A comparative analysis with the national lung cancer audit. Lung Cancer 140, 27–34 (2020). (PMID: 3184678510.1016/j.lungcan.2019.11.023)
Lindsay, C. R. & Blackhall, F. H. Direct Ras G12C inhibitors: crossing the rubicon. Br. J. Cancer 121, 197–198 (2019). (PMID: 31239544673807410.1038/s41416-019-0499-1)
معلومات مُعتمدة: A20465 United Kingdom CRUK_ Cancer Research UK
المشرفين على المادة: 0 (Biomarkers, Tumor)
تواريخ الأحداث: Date Created: 20210907 Date Completed: 20211216 Latest Revision: 20220804
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8548341
DOI: 10.1038/s41416-021-01407-9
PMID: 34489586
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1827
DOI:10.1038/s41416-021-01407-9